BIO in the 13F filings
Bio Rad Labs Inc · CUSIP 090572207
- Quarter end
- 30 Jun 2026
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 3 Aug 2026
- Managers listing it
- 28
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q1 2026 and Q2 2026; 7 listed it in both
- Shares listed
- 4,417,401
- combined, among listed positions
- Reported value
- $1.3bn
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 15 buyers (opened or added shares) and 13 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -403,488.
Managers listing BIO in Q2 2026
28 of 28 holders
Largest increases and reductions, by shares
Increases
- Neuberger Berman Group LLCexisting position · 111,812 shares now+108,783
- AQR Capital Management LLCexisting position · 192,711 shares now+98,162
- Wellington Management Group LLPnew position · 60,249 shares now+60,249
- Capital Research Global Investorsexisting position · 443,483 shares now+57,904
- Millennium Management LLCexisting position · 59,895 shares now+56,601
Reductions
- MFS Investment Managementexisting position · 7,850 shares now-388,300
- Citadel Advisors LLCexisting position · 60,819 shares now-87,850
- Acadian Asset Management LLCexisting position · 21,359 shares now-81,441
- Man Group PLCexisting position · 1,437 shares now-65,999
- T. Rowe Price Associates Incexisting position · 19,287 shares now-54,994
New positions and exits
New (4)
Exited (2)
- Southeastern Asset Management Incwas $45m
- Bridgewater Associates LPwas $469k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 5 | $24m | n.a. | n.a. |
| Q3 2013 | 4 | $22m | n.a. | n.a. |
| Q4 2013 | 2 | $13m | n.a. | n.a. |
| Q1 2014 | 3 | $34m | n.a. | n.a. |
| Q2 2014 | 4 | $33m | n.a. | n.a. |
| Q3 2014 | 5 | $22m | n.a. | n.a. |
| Q4 2014 | 5 | $41m | n.a. | n.a. |
| Q1 2015 | 8 | $145m | n.a. | n.a. |
| Q2 2015 | 6 | $170m | n.a. | n.a. |
| Q3 2015 | 7 | $201m | n.a. | n.a. |
| Q4 2015 | 7 | $186m | n.a. | n.a. |
| Q1 2016 | 6 | $182m | n.a. | n.a. |
| Q2 2016 | 4 | $188m | n.a. | n.a. |
| Q3 2016 | 4 | $224m | n.a. | n.a. |
| Q4 2016 | 7 | $317m | n.a. | n.a. |
| Q1 2017 | 9 | $340m | n.a. | n.a. |
| Q2 2017 | 8 | $298m | n.a. | n.a. |
| Q3 2017 | 4 | $294m | n.a. | n.a. |
| Q4 2017 | 13 | $478m | n.a. | n.a. |
| Q1 2018 | 13 | $524m | n.a. | n.a. |
| Q2 2018 | 15 | $657m | n.a. | n.a. |
| Q3 2018 | 16 | $686m | n.a. | n.a. |
| Q4 2018 | 16 | $498m | n.a. | n.a. |
| Q1 2019 | 15 | $689m | n.a. | n.a. |
| Q2 2019 | 14 | $614m | n.a. | n.a. |
| Q3 2019 | 16 | $801m | n.a. | n.a. |
| Q4 2019 | 12 | $585m | n.a. | n.a. |
| Q1 2020 | 12 | $695m | n.a. | n.a. |
| Q2 2020 | 19 | $1.3bn | n.a. | n.a. |
| Q3 2020 | 17 | $1.7bn | n.a. | n.a. |
| Q4 2020 | 13 | $2.2bn | n.a. | n.a. |
| Q1 2021 | 15 | $2.2bn | n.a. | n.a. |
| Q2 2021 | 18 | $2.7bn | n.a. | n.a. |
| Q3 2021 | 16 | $3.5bn | n.a. | n.a. |
| Q4 2021 | 19 | $3.3bn | n.a. | n.a. |
| Q1 2022 | 22 | $2.4bn | n.a. | n.a. |
| Q2 2022 | 15 | $1.2bn | n.a. | n.a. |
| Q3 2022 | 17 | $857m | n.a. | n.a. |
| Q4 2022 | 16 | $782m | n.a. | n.a. |
| Q1 2023 | 11 | $833m | n.a. | n.a. |
| Q2 2023 | 16 | $607m | n.a. | n.a. |
| Q3 2023 | 15 | $662m | n.a. | n.a. |
| Q4 2023 | 11 | $534m | 8 | 5 |
| Q1 2024 | 7 | $342m | 4 | 6 |
| Q2 2024 | 6 | $409m | 3 | 2 |
| Q3 2024 | 9 | $708m | 7 | 1 |
| Q4 2024 | 11 | $649m | 5 | 4 |
| Q1 2025 | 10 | $612m | 6 | 3 |
| Q2 2025 | 8 | $780m | 4 | 3 |
| Q3 2025 | 8 | $983m | 4 | 3 |
| Q4 2025 | 9 | $1.2bn | 12 | 21 |
| Q1 2026 | 8 | $1.2bn | 18 | 14 |
| Q2 2026 | 7 | $1.1bn | 15 | 13 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
BIO and LLY →BIO and JNJ →BIO and VRTX →Choose a stock to compare with BIO →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own BIO, latest filings →Back to the 13F Explorer →